HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFRA Compliance Program

This article was originally published in The Rose Sheet

Executive Summary

International testing laboratory Eurofins Scientific will conduct third round of product testing to ensure compliance with formulation standards in International Fragrance Association's Code of Practice, according to May 5 release. With 8,000 employees across 150 sites in 29 countries, Eurofins offers "an unparalleled range of testing and support services to the pharmaceutical, food, environmental and consumer products industries, as well as governments," IFRA says. Eurofins picked up testing early this year where the Institute Battelle Laboratories left off when they closed their Swiss-based test lab, the trade group notes. The fragrance industry has earned perfect marks for the last two years, with "not one single banned ingredient [discovered] above the reliable threshold of detection (0.01%)" (1"The Rose Sheet" June 2, 2008, p. 6). Again this year a combination of 50 fragrance, cosmetic and household products, selected randomly from 10 IFRA member countries, will be analyzed

You may also be interested in...



Fragrance Association Reports 100% Compliance With Industry Standards

The International Fragrance Association (IFRA) says 100 percent of member products analyzed in its second round of random testing - from May 2007 to April 2008 - are compliant with the trade group's Code of Practice

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel